DA Davidson analyst Michael Kawamoto raised his price target on Joint Corp to $15 after its Q4 results showed the first quarter of net profitability and another year of 20% comps growth in 2018. The analyst expects the company’s accelerating clinic build-out and efforts to raise its brand awareness to translate into continued margin expansion and earnings growth, keeping his Buy rating on Joint Corp shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.